Iranian Journal of Neurology 2017. 16(4):.

Molecular mechanisms of omega 3 fatty acids in migraine headache
Neda Soveyd, Mina Abdolahi, Sama Bitarafan, Abbas Tafakhori, Payam Sarraf, Mansoureh Togha, Ali Asghar Okhovat, Mahsa Hatami, Mohsen Sedighiyan, Mahmoud Djalali, Niyaz Mohammadzadeh-Honarvar

Abstract


-

Keywords


Omega 3 Fatty Acids; Migraine; Neuroinflammation; Headache

References


Robbins MS, Ailani J. Epidemiology, Progression, Prognosis, and Comorbidity of Trigeminal Autonomic Cephalalgias. Headache. 2013:192-200.

Hamed SA. The vascular risk associations with migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009;205(1):15-22.

Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache: The Journal of Head and Face Pain. 2015;55(1):21-34.

Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache: The Journal of Head and Face Pain. 2001;41(7):646-57.

Goua M, Mulgrew S, Frank J, Rees D, Sneddon A, Wahle K. Regulation of adhesion molecule expression in human endothelial and smooth muscle cells by omega-3 fatty acids and conjugated linoleic acids: involvement of the transcription factor NF-κB? Prostaglandins, Leukotrienes and Essential Fatty Acids. 2008;78(1):33-43.

Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R. Endothelial progenitor cells A new key for endothelial dysfunction in migraine. Neurology. 2012;79(5):474-9.

DosSantos MF, Holanda-Afonso RC, Lima RL, DaSilva AF, Moura-Neto V. The role of the blood–brain barrier in the development and treatment of migraine and other pain disorders. Frontiers in cellular neuroscience. 2014;8.

Forman MS, Lal D, Zhang B, Dabir DV, Swanson E, Lee VM-Y, et al. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. The Journal of neuroscience. 2005;25(14):3539-50.

De Caterina R, Madonna R, Massaro M. Effects of omega-3 fatty acids on cytokines and adhesion molecules. Current atherosclerosis reports. 2004;6(6):485-91.

Calder PC. n− 3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. The American journal of clinical nutrition. 2006;83(6):S1505-19S.

Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia. 2002;40(2):133-9.

Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-34.

Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutrition reviews. 2007;65(suppl 3):S140-S6.

Streit WJ, Mrak RE, Griffin WST. Microglia and neuroinflammation: a pathological perspective. Journal of neuroinflammation. 2004;1(1):14.

Floyd RA. Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radical Biology and Medicine. 1999;26(9):1346-55.

Akiyama H. Inflammatory response in Alzheimer's disease. The Tohoku journal of experimental medicine. 1994;174(3):295-303.

Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiology of aging. 1988;9:339-49.

Liu B, Hong J-S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. Journal of Pharmacology and Experimental Therapeutics. 2003;304(1):1-7.

Maragakis NJ, Rothstein JD. Mechanisms of disease: astrocytes in neurodegenerative disease. Nature clinical practice Neurology. 2006;2(12):679-89.

Danbolt NC. Glutamate uptake. Progress in neurobiology. 2001;65(1):1-105.

Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 1997;276(5319):1699-702.

Nutt JG, Wooten GF. Diagnosis and initial management of Parkinson's disease. New England Journal of Medicine. 2005;353(10):1021-7.

Clement A, Nguyen M, Roberts E, Garcia M, Boillee S, Rule M, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302(5642):113-7.

Takano T, Tian G-F, Peng W, Lou N, Libionka W, Han X, et al. Astrocyte-mediated control of cerebral blood flow. Nature neuroscience. 2006;9(2):260-7.

Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. Journal of the American College of Nutrition. 2002;21(6):495-505.

Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Frontiers in neuroscience. 2014;8.

Nikolaev A, McLaughlin T, O’Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457(7232):981-9.

McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008;5(1):45.

Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009;137(1):47-59.

Sastre M, Walter J, Gentleman SM. Interactions between APP secretases and inflammatory mediators. J Neuroinflammation. 2008;5:25.

Rissman RA, De Blas AL, Armstrong DM. GABAA receptors in aging and Alzheimer’s disease. Journal of neurochemistry. 2007;103(4):1285-92.

Zipp F, Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends in neurosciences. 2006;29(9):518-27.

Pender MP, Greer JM. Immunology of multiple sclerosis. Current allergy and asthma reports. 2007;7(4):285-92.

Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421(6924):744-8.

Thomas K, Estelle B, Mohamed O, Vijay K. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.

Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology. 2009;8(4):382-97.

Davie CA. A review of Parkinson's disease. British medical bulletin. 2008;86(1):109-27.

Braak H, Del Tredici K, Rüb U, de Vos RA, Steur ENJ, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of aging. 2003;24(2):197-211.

Damier P, Hirsch E, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience. 1993;52(1):1-6.

Reynolds AD, Kadiu I, Garg SK, Glanzer JG, Nordgren T, Ciborowski P, et al. Nitrated alpha-synuclein and microglial neuroregulatory activities. Journal of Neuroimmune Pharmacology. 2008;3(2):59-74.

Roodveldt C, Christodoulou J, Dobson CM. Immunological features of α‐synuclein in Parkinson's disease. Journal of cellular and molecular medicine. 2008;12(5b):1820-9.

Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, et al. Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons. PLoS One. 2008;3(1):e1376.

McGeer P, McGeer E. Inflammatory processes in amyotrophic lateral sclerosis. Muscle & nerve. 2002;26(4):459-70.

Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Progress in neurobiology. 2008;85(1):94-134.

Amit I, Garber M, Chevrier N, Leite AP, Donner Y, Eisenhaure T, et al. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science. 2009;326(5950):257-63.

Longoni M, Ferrarese C. Inflammation and excitotoxicity: role in migraine pathogenesis. Neurological Sciences. 2006;27(2):s107-s10.

D’Andrea G, Leon A. Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. Neurological sciences. 2010;31(1):1-7.

Kors EE, Vanmolkot KR, Haan J, Frants RR, van den Maagdenberg AM, Ferrari MD. Recent findings in headache genetics. Current opinion in neurology. 2004;17(3):283-8.

Olsen TSj. Pathophysiology of the migraine aura: the spreading depression theory. Brain. 1995;118(1):307-.

Pietrobon D. Migraine: new molecular mechanisms. The Neuroscientist. 2005;11(4):373-86.

Hargreaves R, Shepheard S. Pathophysiology of migraine—new insights. Canadian Journal of Neurological Sciences/Journal Canadien des Sciences Neurologiques. 1999;26(03):12-9.

Gallai V, Sarchielli P, Coata G, Firenze C, Morucci P, Abbritti G. Serum and salivary magnesium levels in migraine. Results in a group of juvenile patients. Headache: The Journal of Head and Face Pain. 1992;32(3):132-5.

Ramadan N, Halvorson H, Vande‐Linde A, Levine SR, Helpern J, Welch K. Low brain magnesium in migraine. Headache: The Journal of Head and Face Pain. 1989;29(9):590-3.

Huang Q, Gebrewold A, Zhang A, Altura BT, Altura BM. Role of excitatory amino acids in regulation of rat pial microvasculature. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 1994;266(1):R158-R63.

Sun-Edelstein C, Mauskop A. Role of magnesium in the pathogenesis and treatment of migraine. Expert review of neurotherapeutics. 2009;9(3):369-79.

Coan E, Collingridge G. Magnesium ions block an N-methyl-D-aspartate receptor-mediated component of synaptic transmission in rat hippocampus. Neuroscience letters. 1985;53(1):21-6.

Loder E. Mechanism and management of headache. BMJ Publishing Group Ltd; 2005.

Peroutka SJ. Dopamine and migraine. Neurology. 1997;49(3):650-6.

Coppola G, Pierelli F, Schoenen J. Habituation and migraine. Neurobiology of learning and memory. 2009;92(2):249-59.

Hines ML, Carnevale NT. The NEURON simulation environment. Neural computation. 1997;9(6):1179-209.

Durham P, Papapetropoulos S. Biomarkers associated with migraine and their potential role in migraine management. Headache: The Journal of Head and Face Pain. 2013;53(8):1262-77.

Saegusa H, Tanabe T. N-type voltage-dependent Ca 2+ channel in non-excitable microglial cells in mice is involved in the pathophysiology of neuropathic pain. Biochemical and biophysical research communications. 2014;450(1):142-7.

Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutrition reviews. 2010;68(5):280-9.

Xu Z-Z, Zhang L, Liu T, Park JY, Berta T, Yang R, et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nature medicine. 2010;16(5):592-7.

Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Annual review of nutrition. 2011;31:321.

Corsi L, Momo Dongmo B, Avallone R. Supplementation of omega 3 fatty acids improves oxidative stress in activated BV2 microglial cell line. International journal of food sciences and nutrition. 2015;66(3):293-9.

on Aging TNI, on Diagnostic RIWG, Braak H, Coleman P, Dickson D, Duyckaerts C, et al. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiology of aging. 1997;18(4):S1-S2.

Mirra SS, Heyman A, McKeel D, Sumi S, Crain B, Brownlee L, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479-.

Lukiw WJ, Bazan NG. Docosahexaenoic acid and the aging brain. The Journal of nutrition. 2008;138(12):2510-4.

Bazan NG. Neuroprotectin D1 (NPD1): a DHA‐derived mediator that protects brain and retina against cell injury‐induced oxidative stress. Brain pathology. 2005;15(2):159-66.

Montine TJ, Morrow JD. Fatty acid oxidation in the pathogenesis of Alzheimer's disease. The American journal of pathology. 2005;166(5):1283-9.

Farooqui AA, Horrocks LA. Phospholipase A₂-Generated Lipid Mediators in the Brain: The Good, the Bad, and the Ugly. The Neuroscientist. 2006;12(3):245-60.

Calder PC. Dietary modification of inflammation with lipids. Proceedings of the Nutrition Society. 2002;61(03):345-58.

Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. The Journal of pediatrics. 2001;139(2):189-96.

Peet M. Nutrition and schizophrenia: beyond omega-3 fatty acids. Prostaglandins, leukotrienes and essential fatty acids. 2004;70(4):417-22.

Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. Prostaglandins, leukotrienes and essential fatty acids. 2003;69(6):477-85.

Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D, et al. Plasma fatty acid levels in autistic children. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2001;65(1):1-7.

Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, et al. Polyunsaturated fatty acids in the food chain in the United States. The American journal of clinical nutrition. 2000;71(1):179S-88S.

Howe P, Meyer B, Record S, Baghurst K. Contribution of red meat to very long chain omega-3 fatty acid (VLCOmega3) intake. Asia Pac J Clin Nutr. 2003;12:S27.

Layé S. Polyunsaturated fatty acids, neuroinflammation and well being. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA). 2010;82(4):295-303.

Tajmirriahi M, Sohelipour M, Basiri K, Shaygannejad V, Ghorbani A, Saadatnia M. The effects of sodium valproate with fish oil supplementation or alone in migraine prevention: A randomized single-blind clinical trial. Iranian journal of neurology. 2012;11(1):21.

Harel Z, Gascon G, Riggs S, Vaz R, Brown W, Exil G. Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. Journal of Adolescent Health. 2002;31(2):154-61.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.